Sagimet Biosciences Names Andreas Grauer CMO, Grants $1.34M Stock Options
Sagimet Biosciences named Andreas Grauer, MD, as Chief Medical Officer effective April 20, replacing retiring CMO Eduardo Martins, who will serve as an external scientific advisor. To incentivize his joining, the board granted Grauer inducement stock options valued at $1,340,000 vesting over four years.
1. Role Transition and Timing
Sagimet Biosciences appointed Andreas Grauer, MD, as Chief Medical Officer effective April 20, 2026. Outgoing CMO Eduardo Bruno Martins, MD, DPhil, retired on the same date and will continue supporting Sagimet as an external scientific advisor.
2. Inducement Stock Option Details
The Compensation Committee approved an inducement grant of stock options with a fair market value of $1,340,000 based on the Black-Scholes value on April 20, 2026. The options carry a ten-year term, an exercise price equal to the Series A common stock closing price on that date, vesting 25% after one year and the remainder monthly over 36 months.
3. Executive Experience of Dr. Grauer
Dr. Grauer brings over two decades of global biopharmaceutical leadership, including CMO roles at Omeros, Federation Bio and Corcept Therapeutics, senior development positions at Amgen, and early career medical affairs work at Procter & Gamble Pharmaceuticals. He holds an MD and serves as Associate Professor at the University of Heidelberg Medical School, with more than 120 peer-reviewed publications.